|
|
News Breaks | | | | October 18, 2012 | | 08:33 EDT |  | FLML | Flamel announces FDA acceptance of NDA for undisclosed hospital-based product
Flamel Technologies SA announced that the U.S. FDA has accepted the company's New Drug Application, or NDA, for an undisclosed hospital-based product. Flamel has received a Prescription Drug User Fee Act, or PDUFA, date, the target date for the FDA to complete its review of the NDA, of May 31, 2013. For competitive reasons, the Company has decided not to identify the product at this time, but intends to provide additional information at a later date. Flamel believes that the product could have a significant impact on the company's revenue generation and favorably impact its progression to profitability. If approved by the FDA, the product is expected to generate approximately $25M-$35M or more in peak annual revenues, subject to the company being able to market and price the product successfully, of which there can be no assurance. | |
|
News For FLML From The Last 14 Days Check below for free stories on FLML the last two weeks. |
|
|
| May 7, 2013 | | 07:46 EDT |  | FLML | Flamel Technologies reports Q1 EPS (35c), one estimate (33c)
Reports Q1 revenue $5.14M, one estimate $6.11M. | |
|
|
|
|
|
|
